Repository logo
 
Publication

Does the 5–2-1 criteria identify patients with advanced Parkinson's disease? Real-world screening accuracy and burden of 5–2-1-positive patients in 7 countries

2022-01Contribution to journal Open access
Simple item page
datacite.subject.fosCiências Médicas
datacite.subject.sdg03:Saúde de Qualidade
dc.contributor.authorMalaty, Irene A.
dc.contributor.authorMartinez-Martin, Pablo
dc.contributor.authorChaudhuri, K. Ray
dc.contributor.authorOdin, Per
dc.contributor.authorSkorvanek, Matej
dc.contributor.authorJimenez-Shahed, Joohi
dc.contributor.authorSoileau, Michael J.
dc.contributor.authorLindvall, Susanna
dc.contributor.authorDomingos, Josefa
dc.contributor.authorJones, Sarah
dc.contributor.authorAlobaidi, Ali
dc.contributor.authorJalundhwala, Yash J.
dc.contributor.authorKandukuri, Prasanna L.
dc.contributor.authorOnuk, Koray
dc.contributor.authorBergmann, Lars
dc.contributor.authorFemia, Samira
dc.contributor.authorLee, Michelle Y.
dc.contributor.authorWright, Jack
dc.contributor.authorAntonini, Angelo
dc.date.accessioned2025-11-07T09:29:00Z
dc.date.available2025-11-07T09:29:00Z
dc.date.issued2022-01
dc.description.abstractBackground: The burden of Parkinson’s disease (PD) worsens with disease progression. However, the lack of objective and uniform disease classification challenges our understanding of the incremental burden in patients with advanced Parkinson’s disease (APD) and suboptimal medication control. The 5–2-1 criteria was proposed by clinical consensus to identify patients with advancing PD. Our objective was to evaluate the screening accuracy and incremental clinical burden, healthcare resource utilization (HCRU), and humanistic burden in PD patients meeting the 5–2-1 screening criteria. Methods: Data were drawn from the Adelphi Parkinson’s Disease Specific Program (DSP™), a multi-country point-in-time survey (2017–2020). People with PD who were naive to device-aided therapy and on oral PD therapy were included. Patients meeting the 5–2-1 screening criteria had one or more of the three clinical indicators of APD: (i) ≥5 doses of oral levodopa/day, OR (ii) “off” symptoms for ≥2 h of waking day, OR (iii) ≥1 h of troublesome dyskinesia. Clinician assessment of PD stage was used as the reference in this study. Clinical screening accuracy of the 5–2-1 criteria was assessed using area under the curve and multivariable logistic regression models. Incremental clinical, HCRU, and humanistic burden were assessed by known-group comparisons between 5 and 2-1-positive and negative patients. Results: From the analytic sample (n = 4714), 33% of patients met the 5–2-1 screening criteria. Among physician-classified APD patients, 78.6% were 5–2-1 positive. Concordance between clinician judgment and 5–2-1 screening criteria was > 75%. 5–2-1-positive patients were nearly 7-times more likely to be classified as APD by physician judgment. Compared with the 5–2-1-negative group, 5–2-1-positive patients had significantly higher clinical, HCRU, and humanistic burden across all measures. In particular, 5–2-1-positive patients had 3.8-times more falls, 3.6-times higher annual hospitalization rate, and 3.4-times greater dissatisfaction with PD treatment. 5–2-1-positive patients also had significantly lower quality of life and worse caregiver burden. Conclusions: 5–2-1 criteria demonstrated potential as a screening tool for identifying people with APD with considerable clinical, humanistic, and HCRU burden. The 5–2-1 screening criteria is an objective and reliable tool that may aid the timely identification and treatment optimization of patients inadequately controlled on oral PD medications.eng
dc.identifier.citationMalaty, I.A., Martinez-Martin, P., Chaudhuri, K.R. et al. Does the 5–2-1 criteria identify patients with advanced Parkinson's disease? Real-world screening accuracy and burden of 5–2-1-positive patients in 7 countries. BMC Neurol 22, 35 (2022). https://doi.org/10.1186/s12883-022-02560-1
dc.identifier.doi10.1186/s12883-022-02560-1
dc.identifier.issn1471-2377
dc.identifier.urihttp://hdl.handle.net/10400.26/59546
dc.language.isoeng
dc.peerreviewedyes
dc.publisherSpringer Nature
dc.relation.hasversionhttps://doi.org/10.1186/s12883-022-02560-1
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectAdvanced Parkinson’s disease
dc.subject5–2-1 criteria
dc.subjectScreening performance
dc.subjectclinical burden
dc.titleDoes the 5–2-1 criteria identify patients with advanced Parkinson's disease? Real-world screening accuracy and burden of 5–2-1-positive patients in 7 countrieseng
dc.typecontribution to journal
dspace.entity.typePublication
oaire.citation.startPage35
oaire.citation.titleBMC Neurology
oaire.citation.volume22
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Artigo_JosefaDomingos_2022_01.pdf
Size:
1.99 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.85 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

EM - Artigos Científicos